Biogen Inc (NASDAQ: BIIB) has a higher price-to-earnings ratio of 24.20x compared to its average ratio, The 36-month beta value for BIIB is at 0.03. Analysts have varying views on the stock, with 13 analysts rating it as a “buy,” 8 rating it as “overweight,” 11 as “hold,” and 0 as “sell.”
The public float for BIIB is 144.19M, and currently, shorts hold a 2.46% of that float. The average trading volume for BIIB on April 24, 2024 was 1.18M shares.
BIIB) stock’s latest price update
Biogen Inc (NASDAQ: BIIB)’s stock price has plunge by -0.48relation to previous closing price of 194.11. Nevertheless, the company has seen a -1.01% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-19 that Biogen’s (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
BIIB’s Market Performance
Biogen Inc (BIIB) has seen a -1.01% fall in stock performance for the week, with a -11.43% decline in the past month and a -23.24% plunge in the past quarter. The volatility ratio for the week is 2.00%, and the volatility levels for the past 30 days are at 1.94% for BIIB. The simple moving average for the past 20 days is -5.23% for BIIB’s stock, with a -21.10% simple moving average for the past 200 days.
Analysts’ Opinion of BIIB
Many brokerage firms have already submitted their reports for BIIB stocks, with Needham repeating the rating for BIIB by listing it as a “Buy.” The predicted price for BIIB in the upcoming period, according to Needham is $300 based on the research report published on February 14, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see BIIB reach a price target of $240, previously predicting the price at $315. The rating they have provided for BIIB stocks is “Equal Weight” according to the report published on February 14th, 2024.
UBS gave a rating of “Neutral” to BIIB, setting the target price at $276 in the report published on January 24th of the current year.
BIIB Trading at -10.25% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.59% of loss for the given period.
Volatility was left at 1.94%, however, over the last 30 days, the volatility rate increased by 2.00%, as shares sank -10.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.84% lower at present.
During the last 5 trading sessions, BIIB fell by -1.01%, which changed the moving average for the period of 200-days by -29.77% in comparison to the 20-day moving average, which settled at $202.66. In addition, Biogen Inc saw -25.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from Singhal Priya, who sale 93 shares at the price of $213.09 back on Apr 02 ’24. After this action, Singhal Priya now owns 4,886 shares of Biogen Inc, valued at $19,817 using the latest closing price.
Singhal Priya, the Head of Development of Biogen Inc, sale 262 shares at $221.23 during a trade that took place back on Feb 22 ’24, which means that Singhal Priya is holding 4,886 shares at $57,962 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.74 for the gross margin
The net margin for Biogen Inc stands at 0.12. The total capital return value is set at 0.06. Equity return is now at value 8.24, with 4.52 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at 0.5. The interest coverage ratio of the stock is 5.4.
Currently, EBITDA for the company is 2.6 billion with net debt to EBITDA at 2.76. When we switch over and look at the enterprise to sales, we see a ratio of 3.49. The receivables turnover for the company is 4.68for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.00.
Conclusion
In conclusion, Biogen Inc (BIIB) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
